65,437 trials
Major Depressive Disorder
Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -12.2; -15.3 units on a scale — p=0.0051
HIV
Primary: Change in Flow-mediated Dilation (FMD) of the Brachial Artery — -0.67; -0.1 % change from baseline — p=0.67
Multiple Myeloma · Plasma Cell Leukemia
Primary: Overall Survival (OS) — 40 months
Scar Formation
Primary: Photography- Independent Scar Assessment Panel
Stenoses, Carotid Artery
Primary: Overall Perioperative Complications Between Selective vs. Routine Shunting. — 7; 8 Participants — p=<0.05
Asthma
Primary: Cmax of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg — 250; 365; 168; 197…
Asthma
Primary: Change From Baseline in Daytime Composite Symptom Score — 2.73; 2.96; 2.87; -1.38 units on a scale
Rheumatoid Arthritis
Primary: Percentage of Patients With an American College of Rheumatology 20 (ACR20) Response at Week 24 — 60.9; 31.5 Percentage of patients — p=<0.001
Asthma
Primary: Change From Baseline in Daytime Composite Symptom Score — 3.1; 2.8; 2.6; -0.7 units on a scale
Chronic Obstructive Pulmonary Disease
Primary: Incidence of Adverse Events — 3; 3; 6; 7 Participants
Infection Wound · Disruption of Nerve Repair
Primary: 2-point Discrimination Test — 7.5 mm
Painful Digital Neuroma
Primary: Static 2-point Discrimination Test — 7.3 mm
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Best Objective Response — 2 Percentage of participants
Asthma
Primary: Cmax of of Budesonide After Administration of Pulmicort and Three Dose Levels of MAP0010 — 303.5; 106.2; 239.9; 434.5 pg/mL
HIV Infections
Primary: Plasma Viral Loads (HIV-1 RNA PCR) — 92.7; 88 percentage of subjects